抗人活化血小板不同颗粒膜蛋白的单抗在临床上的初步应用

PRELIMINARY CLINICAL APPLICATION OF MONOCLONAL ANTIBODIES TO DIFFERENT GRANULE MEMBRANE PROTEINS EXPRESSED ON SURFACE OF ACTIVATED HUMAN PLATELETS

本文利用单位点免疫放射结合试验来比较抗人血小板α-颗粒膜蛋白(GMP-140)、溶酶体膜蛋白(LIMP-CD63)、溶酶体膜相关蛋白(Lamp-1,Lamp-2)的单抗在检测血小板活化程度方面的应用价值。血小板表面GMP-140的分子数在被检的冠心病、急性心肌梗塞、风湿性心脏病及肺原性心脏病中均呈显著升高(P<0.01);LIMP-CD63分子数仅在冠心病及肺心病中呈显著升高(P<0.05);Lamp-1分子数仅在肺心病中呈显著升高;而Lamp-2分子数均未见显著改变。结果提示4种抗血小板活化标志蛋白的单抗中,GMP-140的单抗可作为疾病状态下判断体内血小板活化程度的指标,LIMP-CD63次之,而Lamp的单抗在疾病中应用价值不大。

Radioimmunoassay was established to detect platelet activation in clinic with 125I labeled monoclonal antibodies to a-granule membrane protein (GMP-140), lysosome integrated membrane protein CD63 (LIMP-CD63), and lysosome associated membrane proteins (Lamp-1, Lamp-2) which were exposed on the surface of activated platelets, respectively. The number of GMP-140 molecules was significantly increased in coronary diseases, acute myocardial infarction, rheumatic cardiac diseases, and pulmonary cardiac diseases (P<0.01). The number of LIMP-CD63 molecules was increased in coronary diseases and pulmonary cardiac diseases (P<0.05). The number of Lamp-1 molecules was increased only in pulmonary cardiac diseases and the number of Lamp-2 molecules was not changed significantly. These results suggest that McAb to GMP-140 could be considered as an index to detecting platelet activation in clinic and next McAb to LIMP-CD63.The value of McAb to Lamp molecules was of no significance in clinic.